Ok, H. O. published the artcileSubstituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonists, Application In Synthesis of 72571-06-3, the publication is Bioorganic & Medicinal Chemistry Letters (2000), 10(14), 1531-1534, database is CAplus and MEDLINE.
As a part of our investigation into the development of orally bioavailable β3 adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent β3 agonists with excellent selectivity against other β receptors. Several of these compounds showed excellent oral bioavailability in dogs. The cyclopentylethyloxazole (I) is a potent β3 agonist (EC50=14 nM, 84% activation) with 340-fold and 160-fold selectivity over β1 and β2 receptors, resp., and has 38% oral bioavailability in dogs.
Bioorganic & Medicinal Chemistry Letters published new progress about 72571-06-3. 72571-06-3 belongs to oxazolidine, auxiliary class Oxazole,Bromide,Benzene, name is 5-(4-Bromophenyl)oxazole, and the molecular formula is C9H6BrNO, Application In Synthesis of 72571-06-3.
Referemce:
https://en.wikipedia.org/wiki/Oxazolidine,
Oxazolidine | C3H7NO – PubChem